Vancomycin prevents polytetrafluoroethylene graft infections in pediatric patients receiving chronic hemodialysis

Am J Kidney Dis. 1985 Feb;5(2):120-3. doi: 10.1016/s0272-6386(85)80007-x.

Abstract

Polytetrafluoroethylene (PTFE) grafts have been a useful addition to the pediatric hemodialysis vascular access armamentarium. In this study, 17 pediatric patients underwent 331 total months of hemodialysis via PTFE grafts. There was a statistically significant (P less than .025) decrease in the incidence of graft infections in 12 patients (235 patient-months) while receiving prophylactic parenteral vancomycin compared with 9 patients (96 patient-months) while receiving no vancomycin (0% v 44%). Vancomycin side effects were uncommon and mild. Vancomycin is a safe and effective agent for the prevention of PTFE graft infections in pediatric patients receiving chronic hemodialysis.

MeSH terms

  • Adolescent
  • Adult
  • Arteriovenous Shunt, Surgical / adverse effects*
  • Arteriovenous Shunt, Surgical / instrumentation
  • Bacterial Infections / prevention & control*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Polytetrafluoroethylene*
  • Prostheses and Implants / adverse effects*
  • Renal Dialysis / methods*
  • Retrospective Studies
  • Vancomycin / therapeutic use*

Substances

  • Vancomycin
  • Polytetrafluoroethylene